Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
This article was originally published in PharmAsia News
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
You may also be interested in...
Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.
Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.
With Pfizer Inc. in the midst of a strategic business review that includes an evaluation of all business units outside the "innovative core," even the company's Established Products business unit - made up of mature pharmaceuticals that have lost exclusivity in developed markets - could be spun out or put up for sale